Helix BioPharma Corp. (TSX, FSE: HBP / OTCQX: HXBPF) announced progress updates for its ongoing Topical Interferon Alpha-2b and L-DOS47 product development programs following pre-investigational new drug (”pre-IND”) meetings with the U.S. Food and Drug Administration (”FDA”). Helix requested the pre-IND meetings in order to confirm its plans for future investigational new drug (”IND”) filings with the FDA.